AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.
For more information, visit http://www.AMPYRA.com.
Do not take AMPYRA if you:
Take AMPYRA exactly as prescribed by your doctor.
Before taking AMPYRA, tell your doctor if you:
Stop taking AMPYRA and call your doctor right away if you have a seizure while taking AMPYRA. You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50. Your doctor may do a blood test to check how well your kidneys are working before you start AMPYRA.
AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.
AMPYRA may cause serious side effects, including severe allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.
The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat.
Please see Patient Medication Guide for additional safety information.
AMPYRA is a registered trademark of Acorda Therapeutics, Inc.
AMPYRA is marketed by Acorda Therapeutics, Inc. and manufactured under license from Alkermes Pharma Limited (APIL), Ireland.